Skip to main content
HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. logo

HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 002900 ISIN · CNE1000032V9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002900

About HARBIN MEDISAN PHARMACEUTICAL CO.,LTD.

https://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co., Ltd. focuses on the research, development, production, and distribution of various medicinal formulations. Its product portfolio encompasses small-volume injections, large-volume injections, lyophilized powder for injection, and solid oral dosage forms such as tablets and capsules. The company specializes in therapeutic categories including cardiovascular and cerebrovascular health, anti-infectives, and gastrointestinal treatments. Utilizing advanced manufacturing technologies and adhering to rigorous quality management systems, the organization aims to provide high-quality therapeutic solutions. Its operations are supported by modern production facilities and a commitment to technical innovation in drug delivery and formulation.

Recent filings

Filing Released Lang Actions
2025年年度股东会的法律意见书
Regulatory Filings Classification · 65% confidence The document is a legal opinion letter (“法律意见书”) issued by Zhong Lun law firm regarding the legality of the company’s 2025 Annual General Meeting (AGM) procedures, attendance, and voting. It is not a presentation to investors (AGM-R or IP), not the official vote results announcement by the company (DVA), nor a proxy solicitation (PSI). It does not contain financial data or serve as a quarterly/annual report. It is a specialized legal counsel opinion, which does not match any specific category except as a miscellaneous regulatory/legal filing. Therefore, it should be classified under the fallback category Regulatory Filings (RNS).
2026-05-19 Chinese
关于参与竞拍资产暨关联交易的进展公告
M&A Activity Classification · 65% confidence The document is an official progress announcement (“进展公告”) by Harbin Sanlian Pharmaceutical Co., Ltd. describing its participation in an auction to acquire bankruptcy assets (a related-party transaction) and the completion of asset registration. It is not a full financial report, earnings release, board/management change, or dividend notice. It’s a transaction announcement concerning asset acquisition (similar to takeover or M&A activity). Therefore, it best fits the M&A Activity category (Code: TAR).
2026-05-19 Chinese
关于参加黑龙江辖区上市公司2026年投资者网上集体接待日活动暨业绩说明会的公告
Regulatory Filings Classification · 80% confidence The document is a short announcement about the company’s participation in an upcoming online investor reception and performance briefing. It contains no substantive financial data or actual presentation materials; it merely notifies investors of an event. This does not fit into a full Investor Presentation (IP) or any financial report, but is a routine regulatory announcement. Therefore it falls under the miscellaneous Regulatory Filings category.
2026-05-11 Chinese
2025年度独立董事述职报告-曾国林（已离任）
Governance Information Classification · 85% confidence The document is a standalone annual performance report by an independent director (“独立董事述职报告”), detailing board attendance, committee work, governance oversight and independent duties. It does not present financial results (so it’s not an Annual Report, IR or ER), nor is it merely a notice of a publication or voting results. It focuses on corporate governance and board practices, aligning with the Governance Information category (Code: CGR).
2026-04-27 Chinese
2025年度财务决算报告
Annual Report Classification · 95% confidence The document is the full 2025 audited annual financial results of Harbin Sanlian Pharmaceutical Co., Ltd., including consolidated balance sheet, income statement, cash flows, notes on major changes and an unqualified auditor’s report. It is a comprehensive yearly report covering all financial performance rather than a brief announcement or presentation. This matches the definition of an Annual Report (10-K). FY 2025
2026-04-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 87% confidence The document is an official announcement by Harbin Sanlian Pharmaceutical Co. regarding changes to its accounting policies following new accounting standard interpretations from the Ministry of Finance. It is not a full financial report (Annual Report or Interim Report), nor an earnings release or investor presentation, and does not fit into any specialized category such as dividends, M&A, or board changes. It is a regulatory disclosure filed with the stock exchange, so it falls under the general “Regulatory Filings” category (RNS).
2026-04-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.